- Type / Class
- Equity / Common Stock
- Shares outstanding
- 164,426,217
- Total 13F shares
- 128,553,808
- Share change
- +6,583,762
- Total reported value
- $1,223,875,095
- Put/Call ratio
- 204%
- Price per share
- $9.52
- Number of holders
- 195
- Value change
- +$58,226,785
- Number of buys
- 117
- Number of sells
- 83
Quarterly Holders Quick Answers
What is CUSIP 26818M108?
CUSIP 26818M108 identifies DYN - Dyne Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 26818M108:
Top shareholders of DYN - Dyne Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Atlas Venture Fund XI, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
6,562,578
|
$165,705,095 | — | 26 Feb 2024 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
6.3%
|
10,353,416
|
$118,465,941 | — | 31 Mar 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
5.9%
|
9,714,392
|
$101,612,540 | — | 31 Mar 2025 | |
| Atlas Venture Life Science Advisors, LLC |
13F
|
Company |
5.6%
|
9,130,465
|
$95,504,664 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
5.8%
from 13D/G
|
8,046,938
|
$84,170,972 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.5%
|
7,406,344
|
$77,470,358 | — | 31 Mar 2025 | |
| Atlas Venture Opportunity Fund I, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,306,079
|
$69,297,674 | — | 01 Mar 2024 | |
| Forbion Capital Fund IV Cooperatief U.A. |
13D/G
|
ForDyne B.V. |
4.8%
|
5,400,545
|
$60,000,055 | $0 | 31 Mar 2025 | |
| FCPM III SERVICES B.V. |
13F
|
Company |
3.3%
|
5,462,846
|
$57,141,369 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
3.2%
|
5,195,294
|
$54,342,775 | — | 31 Mar 2025 | |
| Atlas Venture Opportunity Fund II, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,543,366
|
$44,508,906 | — | 12 Dec 2022 | |
| BRAIDWELL LP |
13F
|
Company |
2.2%
|
3,621,344
|
$37,879,258 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.2%
|
3,609,651
|
$37,756,949 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.8%
|
3,009,389
|
$31,478,209 | — | 31 Mar 2025 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
1.7%
|
2,768,000
|
$28,953,280 | — | 31 Mar 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
1.7%
|
2,717,987
|
$28,430,144 | — | 31 Mar 2025 | |
| TCG Crossover Management, LLC |
13F
|
Company |
1.6%
|
2,650,150
|
$27,720,569 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
1.5%
|
2,531,313
|
$26,477,534 | — | 31 Mar 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
1.4%
|
2,313,403
|
$24,198,195 | — | 31 Mar 2025 | |
| VR Adviser, LLC |
13F
|
Company |
1.3%
|
2,173,913
|
$22,739,130 | — | 31 Mar 2025 | |
| Deep Track Capital, LP |
13F
|
Company |
1.2%
|
2,000,000
|
$20,920,000 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.2%
|
1,955,505
|
$20,459,177 | — | 31 Mar 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1.1%
|
1,820,415
|
$19,043,000 | — | 31 Mar 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
1.1%
|
1,800,000
|
$18,828,000 | — | 31 Mar 2025 | |
| RTW INVESTMENTS, LP |
13D/G
13F
|
Company |
1.5%
|
1,690,567
|
$18,782,199 | -$39,196,902 | 31 Mar 2025 | |
| Point72 Asset Management, L.P. |
13D/G
13F
|
Company |
1.5%
|
1,669,342
|
$18,546,390 | -$39,187,803 | 31 Mar 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
0.88%
|
1,443,341
|
$15,097,347 | — | 31 Mar 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.86%
|
1,414,835
|
$14,799,172 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.85%
|
1,391,587
|
$14,556,001 | — | 31 Mar 2025 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.84%
|
1,388,425
|
$14,522,926 | — | 31 Mar 2025 | |
| Joshua T. Brumm |
3/4/5
|
CEO & President, Director |
—
mixed-class rows
|
621,267
mixed-class rows
|
$13,950,288 | — | 08 Mar 2024 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
0.71%
|
1,167,975
|
$12,218,000 | — | 31 Mar 2025 | |
| Vivo Capital, LLC |
13F
|
Company |
0.68%
|
1,114,960
|
$11,662,482 | — | 31 Mar 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.62%
|
1,014,611
|
$10,612,831 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.61%
|
994,886
|
$10,406,508 | — | 31 Mar 2025 | |
| ArrowMark Colorado Holdings LLC |
13F
|
Company |
0.55%
|
897,946
|
$9,392,515 | — | 31 Mar 2025 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
0.49%
|
812,408
|
$8,497,788 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.44%
|
722,462
|
$7,556,953 | — | 31 Mar 2025 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
0.44%
|
716,896
|
$7,498,732 | — | 31 Mar 2025 | |
| MPM ASSET MANAGEMENT LLC |
13F
|
Company |
0.42%
|
682,376
|
$7,137,653 | — | 31 Mar 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.41%
|
680,836
|
$7,121,545 | — | 31 Mar 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
0.41%
|
672,096
|
$7,030,124 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.4%
|
654,131
|
$6,842,210 | — | 31 Mar 2025 | |
| Wildon Farwell |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
175,353
mixed-class rows
|
$6,588,212 | — | 19 Aug 2024 | |
| Jonathan McNeill |
3/4/5
|
Chief Business Officer |
—
class O/S missing
|
132,106
|
$6,076,876 | — | 19 Aug 2024 | |
| Woodline Partners LP |
13F
|
Company |
0.35%
|
574,435
|
$6,008,590 | — | 31 Mar 2025 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.32%
|
524,499
|
$5,486,260 | — | 31 Mar 2025 | |
| WASATCH ADVISORS LP |
13F
|
Company |
0.31%
|
511,048
|
$5,345,562 | — | 31 Mar 2025 | |
| Logos Global Management LP |
13F
|
Company |
0.3%
|
500,000
|
$5,230,000 | — | 31 Mar 2025 | |
| ALGERT GLOBAL LLC |
13F
|
Company |
0.29%
|
476,007
|
$4,979,000 | — | 31 Mar 2025 |
Institutional Holders of Dyne Therapeutics, Inc. - Common Stock (DYN) as of Q2 2025
As of 30 Jun 2025,
Dyne Therapeutics, Inc. - Common Stock (DYN) was held by
195 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
128,553,808 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., JANUS HENDERSON GROUP PLC, Atlas Venture Life Science Advisors, LLC, BlackRock, Inc., VANGUARD GROUP INC, FCPM III SERVICES B.V., FMR LLC, Siren, L.L.C., TCG Crossover Management, LLC, and STATE STREET CORP.
This page lists
195
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
202
Q2 2025 holders
195
Holder diff
-7
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.